Monthly plans ship freeRead the terms

JournalResearch

How kanna's alkaloids acted in published research

What laboratory assays and five small human studies found, each with its size, design, length and extract. None of them tested THRYVE.

By the THRYVE team4 min read

Small glass sample vials with grey caps in a white rack, some holding a pale amber liquid.
Illustrative image, not a photograph of the lab that tests our batches.

Two targets in the laboratory

In laboratory assays published in 2011, a kanna extract blocked the serotonin transporter and inhibited the enzyme PDE4, but not other phosphodiesterases.*1 The extract was Zembrin, a branded one, and the work used receptor and enzyme assays and cultured cells, with no people or animals.1

The same study tested the purified alkaloids.1 Mesembrine was the most active of them at the first of those targets, mesembrenone acted on both, and the extract showed no toxic effects on mammalian cells.*1

Its authors suggested that these activities may explain the effects reported for kanna preparations.*1 That suggestion has not been tested for our product.2

What the human studies measured

Five human studies are cited here, each against a placebo: four used Zembrin, the fifth does not name its extract, and none tested a THRYVE gummy.345672 They are listed with their size, design, length and extract, because a result means little without them. If you read this the way you read a Supplement Facts panel, the line that matters is the extract: Zembrin four times, unnamed once, a THRYVE gummy never.

In 2013, 16 healthy adults took part in a double-blind, placebo-controlled crossover study with brain imaging (fMRI).3 Two hours after a single 25 mg dose of Zembrin, the amygdala's reactivity to fearful faces, under low perceptual load, was lower than on placebo.*3

In 2014, 21 cognitively healthy adults with a mean age of 54.6 took 25 mg of Zembrin or a placebo once a day for three weeks each, in a randomized, double-blind crossover.5 On Zembrin, their scores for set-shifting and executive function were better than on placebo.*5

In 2016, 60 healthy adults were randomized to a single 25 mg or 50 mg dose of Zembrin or a placebo, in three parallel groups.6 Quantitative EEG, with eye-tracking, recorded changes in the brain's electrical activity during mental tasks.*6

The longest of the five ran for three months and measured tolerability only: in 2013, 37 healthy adults took 8 mg or 25 mg of Zembrin, or a placebo, once a day, randomized and double-blind; both doses were well tolerated; the trial did not measure any benefit.4

Also in 2020, 60 trained adults aged 20 to 35 took a 25 mg kanna extract or a placebo every day for eight days, in two randomized parallel groups; the abstract does not name the extract.7 Tested two hours after the dose on day 8, the extract group improved on complex reaction tasks, and their mood did not change.*7

One more study used animals, and we list it because it is cited elsewhere. In a chick model, an injected, alkaloid-rich kanna fraction, not Zembrin, reduced distress calls.*8 Animal results do not show effects in people.8

What this does and does not show

Every human study cited here was placebo-controlled, small (60 people or fewer), short (one dose to 3 months) and in healthy adults, and four of the five used Zembrin.934567 Each measured something different: brain imaging, thinking tests, brain activity, tolerability, reaction time.34567 That is the honest size of the evidence, and we print it beside each finding rather than once at the bottom. More studies would not change that by themselves; what matters is who took part, against what, for how long, and with which extract.

No published source gives kanna's typical onset or how long its effects last.37 The two placebo-controlled studies that timed their measures took them 2 hours after a 25 mg dose: the imaging study of 16 adults on Zembrin, and the 8-day study of 60 adults on an unnamed extract.37

These are findings about kanna's alkaloids, mostly in one branded extract. Our extract has not been studied, and a study's milligrams describe its own extract, not ours, so none of them is a claim about a THRYVE gummy.2

None of these results came from our gummy, and none of them is a reason to take more than the pouch says.2

Each starred sentence above describes a result in published research, and the note at the foot of this page says what the star means. What would change this page is a larger study, of longer duration, of the extract we use. When one exists, it goes here, with its size printed the same way.

Who should not take it

The pouch is specific about this, and we quote it in full.

ADULTS 21+

WARNING: Effects vary by individual.

Do not use if you take an SSRI, SNRI, MAOI, tricyclic antidepressant, triptan, or any other medication that affects serotonin.

Consult a physician before use if you take any prescription medication, have a medical condition, or are pregnant or nursing.

Keep out of reach of children.

A review published in 2021 found no reports to date of severe adverse reactions or herb-drug interactions, and still advises caution with medication of the kind the second warning line names; it also flags medicines that act on the enzyme PDE4.10

* Marks a statement about what kanna or its alkaloids did in published research, or how a historical writer described it. None of it is a claim about this product.

[?]These statements made have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

References

Numbered in the order each source is first cited on this page. Titles are printed as their publishers printed them.

  1. Harvey AL, Young LC, Viljoen AM, Gericke NP (2011). Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. Journal of Ethnopharmacology 137(3):1124-1129. doi:10.1016/j.jep.2011.07.035 Back to the text
  2. THRYVE (client) (2026). THRYVE kanna gummies pouch: front, Supplement Facts, directions, warning. Back to the text
  3. Terburg D, Syal S, Rosenberger LA, Heany S, Phillips N, Gericke N, Stein DJ, van Honk J (2013). Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Neuropsychopharmacology 38(13):2708-2716. doi:10.1038/npp.2013.183 Back to the text
  4. Nell H, Siebert M, Chellan P, Gericke N (2013). A randomized, double-blind, parallel-group, placebo-controlled trial of Extract Sceletium tortuosum (Zembrin) in healthy adults. Journal of Alternative and Complementary Medicine 19(11):898-904. doi:10.1089/acm.2012.0185 Back to the text
  5. Chiu S, Gericke N, Farina-Woodbury M, Badmaev V, Raheb H, Terpstra K, Antongiorgi J, Bureau Y, Cernovsky Z, Hou J, Sanchez V, Williams M, Copen J, Husni M, Goble L (2014). Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia. Evidence-Based Complementary and Alternative Medicine 2014:682014. doi:10.1155/2014/682014 Back to the text
  6. Dimpfel W, Gericke N, Suliman S, Chiegoua Dipah GN (2016). Psychophysiological Effects of Zembrin® Using Quantitative EEG Source Density in Combination with Eye-Tracking in 60 Healthy Subjects. A Double-Blind, Randomized, Placebo-Controlled, 3-Armed Study with Parallel Design. Neuroscience and Medicine (Scientific Research Publishing) 7(3):114-132. doi:10.4236/nm.2016.73013 Back to the text
  7. Hoffman JR, Markus I, Dubnov-Raz G, Gepner Y (2020). Ergogenic Effects of 8 Days of Sceletium Tortuosum Supplementation on Mood, Visual Tracking, and Reaction in Recreationally Trained Men and Women. Journal of Strength and Conditioning Research 34(9):2476-2481. doi:10.1519/JSC.0000000000003693 Back to the text
  8. Carpenter JM, Jourdan MK, Fountain EM, Ali Z, Abe N, Khan IA, Sufka KJ (2016). The effects of Sceletium tortuosum (L.) N.E. Br. extract fraction in the chick anxiety-depression model. Journal of Ethnopharmacology 193:329-332. doi:10.1016/j.jep.2016.08.019 Back to the text
  9. Olatunji TL, Siebert F, Adetunji AE, Harvey BH, Gericke J, Hamman JH, Van der Kooy F (2022). Sceletium tortuosum: A review on its phytochemistry, pharmacokinetics, biological, pre-clinical and clinical activities. Journal of Ethnopharmacology 287:114711. doi:10.1016/j.jep.2021.114711 Back to the text
  10. Brendler T, Brinckmann JA, Feiter U, Gericke N, Lang L, Pozharitskaya ON, Shikov AN, Smith M, Van Wyk BE (2021). Sceletium for Managing Anxiety, Depression and Cognitive Impairment: A Traditional Herbal Medicine in Modern-Day Regulatory Systems. Current Neuropharmacology 19(9):1384-1400. doi:10.2174/1570159X19666210215124737 Back to the text

More from the journal

  1. The plant4 min readWhat kanna is
  2. History4 min readA short history of kanna
  3. Dose and safety4 min readDose and safety, from the pouch and the research